Display options
Share it on

World J Hepatol. 2018 Jan 27;10(1):166-171. doi: 10.4254/wjh.v10.i1.166.

Contrast uptake in primary hepatic angiosarcoma on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the hepatobiliary phase.

World journal of hepatology

Manabu Hayashi, Satoshi Kawana, Hirofumi Sekino, Kazumichi Abe, Naoki Matsuoka, Masahito Kashiwagi, Ken Okai, Yukiko Kanno, Atsushi Takahashi, Hiroshi Ito, Yuko Hashimoto, Hiromasa Ohira

Affiliations

  1. Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
  2. Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
  3. Department of Radiology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.

PMID: 29399290 PMCID: PMC5787680 DOI: 10.4254/wjh.v10.i1.166

Abstract

Primary hepatic angiosarcoma is the most common malignant mesenchymal tumor of the liver. It has a poor prognosis and various appearances on magnetic resonance (MR) images. We report a case of hepatic angiosarcoma with a characteristic appearance on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging in the hepatobiliary phase. A 72-year-old man was admitted with a complaint of abdominal pain. Gd-EOB-DTPA-enhanced MR imaging revealed a liver tumor that showed slight hyperintensity in the hepatobiliary phase. These findings suggested Gd-EOB-DTPA uptake in the tumor. An autopsy revealed the solid proliferation and sinusoidal spreading of hepatic angiosarcoma cells. Immunohistochemistry indicated that the tumor was negative for OATP1B3. Gd-EOB-DTPA uptake in the liver tumor in the hepatobiliary phase suggested sinusoidal tumor invasion with residual normal hepatocytes.

Keywords: Cirrhosis; Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid; Hepatic angiosarcoma; Hepatocellular carcinoma

Conflict of interest statement

Conflict-of-interest statement: There are no conflicts of interest to declare.

References

  1. Radiology. 2010 Sep;256(3):817-26 - PubMed
  2. Hepatol Res. 2014 Oct;44(10):E297-303 - PubMed
  3. Radiographics. 1994 Jan;14 (1):153-66; quiz 167-8 - PubMed
  4. Cancer. 2007 Apr 1;109(7):1391-6 - PubMed
  5. Liver Cancer. 2012 Nov;1(3-4):190-200 - PubMed
  6. Medicine (Baltimore). 1979 Jan;58(1):48-64 - PubMed
  7. J Hepatobiliary Pancreat Surg. 2003;10(3):250-2 - PubMed
  8. Arch Pathol Lab Med. 1985 Sep;109(9):853-7 - PubMed
  9. Ann Oncol. 2009 Apr;20(4):780-7 - PubMed
  10. Int Surg. 1975 Apr;60(4):198-203 - PubMed
  11. Radiology. 2002 Mar;222(3):667-73 - PubMed
  12. Transplantation. 2013 Mar 27;95(6):872-7 - PubMed
  13. Liver Cancer. 2014 May;3(2):97-107 - PubMed
  14. Liver Cancer. 2017 Jun;6(3):189-203 - PubMed
  15. Br J Radiol. 2012 Sep;85(1017):e573-83 - PubMed
  16. J Gastroenterol. 2009;44(7):793-8 - PubMed
  17. Jpn J Radiol. 2011 Aug;29(7):524-7 - PubMed
  18. Eur Radiol. 2015 Feb;25(2):315-22 - PubMed
  19. Oncol Rep. 1997 May-Jun;4(3):525-9 - PubMed
  20. Am Surg. 2000 Dec;66(12 ):1153-7 - PubMed

Publication Types